Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06734312 · ClinicalTrials.gov registry record · NA

MAINTAIN (Mucosal AblatIoN Therapy After INcretins)

A NA study of Obesity and Overweight and Obesity and Obesity-related Medical Conditions, sponsored by Dr. Christopher McGowan.

Recruiting
Registry status
NA
Development phase
20
Enrollment target
2
Study locations

NCT06734312: Recruiting NA study of Obesity and Overweight and Obesity and Obesity-related Medical Conditions, sponsored by Dr. Christopher McGowan.

NCT06734312 is a NA study of Obesity and Overweight and Obesity and Obesity-related Medical Conditions that is actively recruiting participants, run by Dr. Christopher McGowan. The registered enrollment target is 20 participants, below the 465-participant average among 27 other Obesity and Overweight trials with a reported enrollment target (96% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06734312, a NA study of Obesity and Overweight and Obesity and Obesity-related Medical Conditions, is actively recruiting participants, sponsored by Dr. Christopher McGowan.

RECRUITING
Registry status
NA
Development phase
20 participants
Enrollment target
2
Study locations

Study Summary

The purpose of this study is to assess the effect of gastric fundal mucosal ablation (GFMA) on weight trajectory following discontinuation of once-weekly semaglutide or tirzepatide in adults with obesity. In this study, GFMA will be performed on patients who have experienced \> 10% weight loss with GLP-1 therapy and who plan to discontinue use of GLP-1 medications for the duration of the study.

Primary Outcome

Measure percent change in total body weight over time following endoscopic GFMA. TBWL = pre-op weight - post op body weight. % TBWL is the fraction of body weight expressed in percentage term

Conditions Studied

Obesity and Overweight Obesity and Obesity-related Medical Conditions Obesity Prevention GLP-1 Obesity Recidivism Ablation Techniques

Interventions

  • DEVICE Gastric Fundal Mucosal Ablation (GFMA)

Study Locations (2)

North Carolina

  • True You Weight Loss - Cary
  • True You Weight Loss - Cary

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2025-01-01
Est. Completion 2026-06
Phase NA
Dr. Christopher McGowan

2 total trials

What NCT06734312 shows while recruiting

NCT06734312 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 465-participant average among 27 other Obesity and Overweight trials with a reported enrollment target (96% lower).

The record links to 6 conditions, with Obesity and Overweight appearing as the primary indexed condition, and to 1 intervention - of which Gastric Fundal Mucosal Ablation (GFMA) is the first listed.

NCT06734312 reports a single indexed study location in North Carolina.

Frequently Asked Questions

What is clinical trial NCT06734312 about?

NCT06734312 is a clinical study titled "MAINTAIN (Mucosal AblatIoN Therapy After INcretins)". The purpose of this study is to assess the effect of gastric fundal mucosal ablation (GFMA) on weight trajectory following discontinuation of once-weekly semaglutide or tirzepatide in adults with obesity. In this study, GFMA will be performed on patients who have experienced \> 10% weight loss with ...

What is the current status of trial NCT06734312?

This trial is currently recruiting. It is a NA study. The enrollment target is 20 participants. The study started on 2025-01-01. Estimated completion is 2026-06.

What conditions does trial NCT06734312 study?

This clinical trial studies the following conditions: Obesity and Overweight, Obesity and Obesity-related Medical Conditions, Obesity Prevention, GLP-1, Obesity Recidivism.

What interventions are being tested in trial NCT06734312?

The interventions under investigation include: Gastric Fundal Mucosal Ablation (GFMA) (DEVICE).

Who is sponsoring clinical trial NCT06734312?

This trial is sponsored by Dr. Christopher McGowan, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06734312 being conducted?

This trial has 2 study locations across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Obesity and Overweight

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06734312's enrollment target sits among peer trials

20 25th of 27 higher than 2 of 27 other Obesity and Overweight trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Obesity and Overweight trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00573339 · 20 participants

    Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing

  • NCT00692939 · 20 participants · Phase 1

    Autologous Stem Cell Transplantation for Crohn's Disease

  • NCT00967785 · 20 participants · Phase 1

    A Phase I Study of Mozobil in the Treatment of Patients With WHIMS

  • NCT01406691 · 20 participants · Phase 4

    Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06734312

Source: ClinicalTrials.gov NCT06734312, the US trial registry maintained by the National Library of Medicine. NCT06734312 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.